Relmada Therapeutics Inc (NAS:RLMD)
$ 3.05 -0.06 (-1.93%) Market Cap: 92.03 Mil Enterprise Value: 10.23 Mil PE Ratio: 0 PB Ratio: 1.28 GF Score: 31/100

Relmada Therapeutics Inc REL-1017 Clinical Data Update Call Transcript

Jul 27, 2021 / 12:30PM GMT
Release Date Price: $25.61 (+1.95%)
Operator

Greetings. Welcome to Relmada Therapeutics Corporate Update Call. (Operator Instructions) Please note this conference is being recorded.

At this time, I'll now turn the conference over to Tim McCarthy with LifeSci Advisors.

Tim, you may now begin.

Timothy McCarthy
LifeSci Advisors, LLC - MD & Relationship Manager

Thank you, operator, and thank you all for joining us this morning. As Slide 2 states, please note that certain information discussed on the call today is covered under the safe harbor provision of the Private Securities Litigation Reform Act.

We caution listeners that during this call, Relmada's management team will be making forward-looking statements. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in Relmada's press release issued today and the company's SEC filings, including the annual report on Form 10

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot